Table 1 Selected baseline and clinical characteristics of men with prostate cancer
From: Metabolomic profile of prostate cancer-specific survival among 1812 Finnish men
Characteristic a | Died from prostate cancer (N = 472) | Did not die from prostate cancer (N = 1340) |
|---|---|---|
Age at blood collection, years, median (interquartile range) | 58.0 (54.0–62.0) | 57.0 (53.0–61.0) |
Age at cancer diagnosis, years, median (interquartile range) | 69.0 (65.0–73.0) | 71.0 (68.0–75.0) |
Time from baseline to cancer diagnosis, years, median (interquartile range) | 11.0 (8.0–15.0) | 14.0 (11.0–18.0) |
BMI (kg/m2) | 26.2 (3.6) | 26.3 (3.6) |
Serum total cholesterol (mmol/L) | 6.2 (1.1) | 6.2 (1.1) |
Serum HDL cholesterol (mmol/L) | 1.2 (0.3) | 1.2 (0.3) |
Serum α-tocopherol (mg/L) | 11.8 (3.1) | 11.8 (3.1) |
Serum β-carotene (μg/L) | 228 (205) | 225 (178) |
Serum retinol (μg/L) | 601 (128) | 595 (129) |
Cigarette per day | 19 (8) | 20 (9) |
Years of cigarette smoking | 36 (9) | 35 (9) |
Diagnosis period, No. (%) | ||
 1986–1994 | 191 (40.4) | 253 (18.9) |
 1995–2000 | 165 (35.0) | 478 (35.7) |
 2001–2010 | 116 (24.6) | 609 (45.5) |
Cancer stage, No. (%) | ||
 Stage I | 73 (15.5) | 580 (43.3) |
 Stage II | 113 (23.9) | 517 (38.6) |
 Stage III | 72 (15.3) | 169 (12.6) |
 Stage IV | 214 (45.3) | 74 (5.5) |
Gleason score, No. (%) | ||
 1–6 | 112 (23.7) | 698 (52.1) |
 7 | 103 (21.8) | 282 (21.0) |
 8–10 | 120 (25.4) | 131 (9.8) |
 Unknown | 137 (29.0) | 229 (17.1) |
Median survival time for all case patients (years) | 5.0 (4.1) | 8.3 (5.4) |
Median survival time for case patients by stage (years) | ||
 Stage I | 7.8 (4.4) | 8.3 (5.1) |
 Stage II | 6.4 (3.8) | 8.5 (5.7) |
 Stage III | 5.9 (4.3) | 9.3 (5.6) |
 Stage IV | 3.1 (3.0) | 5.3 (5.0) |
Median survival time for case patients by Gleason score (years) | ||
 1–6 | 6.5 (4.6) | 8.8 (5.5) |
 7 | 5.0 (3.6) | 8.1 (4.8) |
 8–10 | 3.8 (3.1) | 6.2 (5.0) |
 Unknown | 5.0 (4.5) | 8.5 (6.1) |